OBJECTIVES: To examine the all-cause mortality rate and factors associated with mortality in US veteran men with RA. METHODS: Men with RA were enrolled and followed until death or censoring. Vital status was ascertained through systematic record review and standardized mortality ratios (SMRs) were calculated using US life tables for men. Multivariate Cox proportional hazards regression was used to examine the independent associations of patient factors including socio-demographics, comorbidity, measures of RA disease activity/severity and medication use with mortality. Measures of RA disease activity and medications were examined as time-varying factors. RESULTS: A total of 138 deaths were observed during 2314 patient-years of follow-up (n=1015 patients), corresponding to a crude morality rate of 5.9 deaths per 100 patient-years (95% CI 5.0, 7.0) and an SMR of 2.1 (95% CI 1.8, 2.5). After multivariate adjustment, factors independently associated with higher mortality risk in men with RA included older age, Caucasian race, low body weight, an increased frequency of rheumatology visits, higher ESR and RF concentrations, increased DAS28, subcutaneous nodules and prednisone use. In contrast, MTX use [hazard ratio (HR) 0.63; 95% CI 0.42, 0.96] was associated with ∼40% lower mortality risk. CONCLUSION: Mortality rates among US male veterans with RA are more than twice those of age-matched men in the general population. These results suggest that optimizing disease control, particularly with regimens that include MTX and minimize glucocorticoid exposure, could improve long-term survival in this population.
OBJECTIVES: To examine the all-cause mortality rate and factors associated with mortality in US veteran men with RA. METHODS:Men with RA were enrolled and followed until death or censoring. Vital status was ascertained through systematic record review and standardized mortality ratios (SMRs) were calculated using US life tables for men. Multivariate Cox proportional hazards regression was used to examine the independent associations of patient factors including socio-demographics, comorbidity, measures of RA disease activity/severity and medication use with mortality. Measures of RA disease activity and medications were examined as time-varying factors. RESULTS: A total of 138 deaths were observed during 2314 patient-years of follow-up (n=1015 patients), corresponding to a crude morality rate of 5.9 deaths per 100 patient-years (95% CI 5.0, 7.0) and an SMR of 2.1 (95% CI 1.8, 2.5). After multivariate adjustment, factors independently associated with higher mortality risk in men with RA included older age, Caucasian race, low body weight, an increased frequency of rheumatology visits, higher ESR and RF concentrations, increased DAS28, subcutaneous nodules and prednisone use. In contrast, MTX use [hazard ratio (HR) 0.63; 95% CI 0.42, 0.96] was associated with ∼40% lower mortality risk. CONCLUSION: Mortality rates among US male veterans with RA are more than twice those of age-matched men in the general population. These results suggest that optimizing disease control, particularly with regimens that include MTX and minimize glucocorticoid exposure, could improve long-term survival in this population.
Authors: Carl Turesson; W Michael O'Fallon; Cynthia S Crowson; Sherine E Gabriel; Eric L Matteson Journal: J Rheumatol Date: 2002-01 Impact factor: 4.666
Authors: B J Radovits; J Fransen; S Al Shamma; A M Eijsbouts; P L C M van Riel; R F J M Laan Journal: Arthritis Care Res (Hoboken) Date: 2010-03 Impact factor: 4.794
Authors: J Steuart Richards; Justin Peng; Richard L Amdur; Ted R Mikuls; Roderick S Hooker; Kaleb Michaud; Andreas M Reimold; Grant W Cannon; Liron Caplan; Dannette Johnson; Anne E Hines; Gail S Kerr Journal: J Clin Densitom Date: 2009-09-23 Impact factor: 2.617
Authors: Sarah L Westlake; Alexandra N Colebatch; Janis Baird; Patrick Kiely; Mark Quinn; Ernest Choy; Andrew J K Ostor; Christopher J Edwards Journal: Rheumatology (Oxford) Date: 2009-11-27 Impact factor: 7.580
Authors: Angel Gonzalez; Hilal Maradit Kremers; Cynthia S Crowson; Paulo J Nicola; John M Davis; Terry M Therneau; Veronique L Roger; Sherine E Gabriel Journal: Arthritis Rheum Date: 2007-11
Authors: Joshua F Baker; Grant W Cannon; Said Ibrahim; Candace Haroldsen; Liron Caplan; Ted R Mikuls Journal: J Rheumatol Date: 2015-04-01 Impact factor: 4.666
Authors: Joshua F Baker; Bryant R England; Ted R Mikuls; Harlan Sayles; Grant W Cannon; Brian C Sauer; Michael D George; Liron Caplan; Kaleb Michaud Journal: Arthritis Care Res (Hoboken) Date: 2018-12 Impact factor: 4.794
Authors: Leann B Maska; Harlan R Sayles; James R O'Dell; Jeffrey R Curtis; S Louis Bridges; Larry W Moreland; Stacey S Cofield; Ted R Mikuls Journal: Arthritis Care Res (Hoboken) Date: 2012-12 Impact factor: 4.794
Authors: Diana S Novikova; Helen V Udachkina; Eugenia I Markelova; Irina G Kirillova; Anna S Misiyuk; Natalia V Demidova; Tatiana V Popkova Journal: Rheumatol Int Date: 2019-05-03 Impact factor: 2.631
Authors: Pascale Schwab; Harlan Sayles; Debra Bergman; Grant W Cannon; Kaleb Michaud; Ted R Mikuls; Jennifer Barton Journal: Arthritis Care Res (Hoboken) Date: 2017-05-09 Impact factor: 4.794
Authors: Lewis H Kuller; Rachel H Mackey; Brian T Walitt; Kevin D Deane; V Michael Holers; William H Robinson; Jeremy Sokolove; Yuefang Chang; Simin Liu; Christine G Parks; Nicole C Wright; Larry W Moreland Journal: Arthritis Rheumatol Date: 2014-03 Impact factor: 10.995